Day: May 21, 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlightsSale of Idorsia Asia-Pacific operations (excluding China): Sold to Nxera Pharma (previously known as Sosei Heptares) for a total consideration of CHF 400 million in July 2023. Cost reduction initiative: Delivering a 50% reduction in fixed cost at Swiss headquarters fully effective in early 2024. Aprocitentan: Worldwide rights reacquired from Janssen for a conditional consideration of CHF 306 million in September 2023.Commercial highlightsQUVIVIQ™ (daridorexant): Total net sales of CHF 31 million in 2023. QUVIVIQ: Expanded access and availability in the US, Canada and across Europe.Financial highlights FY 2023Net revenue FY 2023 at CHF...

PINE MOUNTAIN, Georgia, May 20, 2024 (GLOBE NEWSWIRE) — Parks! America, Inc. (OTCPink: PRKA) (“Parks! America” or the “Company”), a leading operator of regional safari parks in the United States, today issued an open letter to the Company’s shareholders outlining the clear choice hanging in the balance at its annual meeting of shareholders scheduled for June 6, 2024. Dear Parks! America Shareholders, After five months of wasting your time and damaging Parks! America by causing the diversion of money and management time, on May 8th the principals of Focused Compounding (“FC”) finally revealed their real “plan”: to liquidate the assets of the Company. It is difficult to tell if this was their plan all along or just another attempt at deploying business management buzzwords to further their dream of conducting a proxy fight with a...

Volvo On DemandVolvo Trucks North America and Volvo Financial Services are collaborating on Volvo on Demand, a joint project to accelerate battery-electric vehicle adoption and redefine the Truck-as-a-Service (TaaS) business model using 25 Class 8 Volvo VNR Electric trucks.Greensboro, N.C., May 20, 2024 (GLOBE NEWSWIRE) — Volvo Trucks North America (VTNA) and Volvo Financial Services (VFS) have joined forces to form Volvo on Demand, a collaborative initiative to change and lead the industry in the Truck-as-a-Service (TaaS) business model. Using 25 Class 8 Volvo VNR Electric trucks, Volvo on Demand was designed as an innovative solution to simplify the acquisition and reduce the major upfront investment in battery-electric vehicles. Volvo on Demand provides qualified customers with flexible term options as short as 12 months...

Purpose designed and built for autonomy; the fully redundant truck will enable autonomous transportVolvo VNL Autonomous Truck (Front View)Volvo Autonomous Solutions (V.A.S.) unveiled Volvo’s first-ever production ready autonomous truck at the Advanced Clean Transportation (ACT) Expo May 20 in Las Vegas.Volvo VNL Autonomous Truck (Side View)The Volvo VNL Autonomous Truck brings together Volvo’s commercial vehicle expertise with industry-leading autonomous driving technology from Aurora Innovation.Greensboro, N.C., May 20, 2024 (GLOBE NEWSWIRE) — Volvo Autonomous Solutions (V.A.S.) today unveiled Volvo’s first-ever production ready autonomous truck at the Advanced Clean Transporation (ACT) Expo in Las Vegas. The Volvo VNL Autonomous brings together Volvo’s commercial vehicle expertise with industry-leading autonomous...

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira®REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars...

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira®REYKJAVIK, ICELAND & PARSIPPANY, NJ  — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings...